Deutetrabenazine

BreastfeedingGeriatricPediatric

FDA APPROVAL DATE: 04/03/2017

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alcohol or other sedating drugs, Bupropion, Dopamine antagonists or antipsychotics, Fluoxetine, MAO inhibitors, Paroxetine Hydrochloride, Quinidine, Strong CYP2D6 inhibitors, Tetrabenazine

PREGNANCY CATEGORY: N/A
Based on animal data, may cause fetal harm

Contra-indicated in suicidal or untreated/inadequately treated depression, in hepatic impairment. or in patients taking MAO inhibitors, reserpine or tetrabenazine.

DEPRESSION AND SUICIDALITY

See full prescribing information for complete boxed warning.

Our database has 21 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.


Page last updated 10/19/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top